|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.45 - 2.85|
|52 Week Range||2.25 - 5.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.50|
After looking at Compugen Ltd’s (NASDAQ:CGEN) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
Compugen Ltd (NASDAQ:CGEN), a life sciences tools and services company based in Israel, received a lot of attention from a substantial price movement on the NasdaqGM in the over theRead More...
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 10:00 AM Eastern Time. ...
On a per-share basis, the Holon, Israel-based company said it had a loss of 19 cents. The company's shares closed at $3. A year ago, they were trading at $5.95. _____ This story was generated by Automated ...
- Phase I Study for COM701 Expected to Start in 2018 - IND Application for COM902 Anticipated in 2019 HOLON, Israel , Nov. 7, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery ...
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with Mount Sinai, under the direction of Miriam Merad, MD, PhD, Director of the Precision Immunology Institute and Co-Leader of the Cancer Immunology program and Mount Sinai Professor in Cancer Immunology at the Icahn School of Medicine at Mount Sinai in New York. Dr. Merad is a world-class leader in the field of myeloid biology for the development of novel cancer immunotherapies and is a member of Compugen's Scientific Advisory Board (SAB).
Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it will present two posters with new data on COM701, the Company's first-in class immuno-oncology therapeutic antibody candidate targeting PVRIG, and COM902, the Company's immuno-oncology therapeutic antibody targeting TIGIT, at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8-12 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "Analysis of the TIGIT/PVRIG axis in human cancers to support indication selection and biomarkers for COM701 and COM902" (Poster no. P369) will be presented on Friday, November 10, 2017 at 12:30-2 pm and 6:30-8 pm ET.
Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its third quarter financial results on Tuesday, November 7, 2017 before the U.S. financial markets open. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.
LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Compugen Ltd (NASDAQ: CGEN ), following which we have published ...
Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.
HOLON, Israel, Oct. 9, 2017 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, disclosed new data demonstrating the potential of CGEN-15032 as a target for the development of first-in-class cancer therapy. CGEN-15032 is a novel myeloid and epithelial immuno-oncology target, which may serve as an immuno-suppressive target within the tumor microenvironment.
If you are looking to invest in Compugen Ltd’s (NASDAQ:CGEN), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology target, will be the subject of both an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference taking place September 6-9, 2017 in Mainz/Frankfurt, Germany. The presentation titled "Computational discovery and experimental validation of CGEN-15032 as a novel target for cancer immunotherapy" is scheduled as part of the session titled "Other checkpoint blocking and immunomodulating antibodies," on Friday, September 8, 2:00-3:45 pm CEST.
Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
The Holon, Israel-based company said it had a loss of 18 cents per share. The company's shares closed at $3.80. A year ago, they were trading at $6.91. _____ This story was generated by Automated Insights ...
Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Board of Directors has appointed Paul Sekhri to serve as a Director and Chairman of the Board, effective October 2, 2017. As the new Chairman, Mr. Sekhri will succeed Martin Gerstel, who announced his intention to retire from this role in February of this year.
IND application for COM701 therapeutic antibody candidate for immuno-oncology expected to be filed towards the end of the first quarter of 2018 Compugen names Paul Sekhri as Chairman of the Board effective ...
HOLON, Israel, July 26, 2017 /PRNewswire/ -- Compugen Ltd. (CGEN), a therapeutic discovery company, announced today updates to its collaborative activities in immuno-oncology with Bayer. The agreement with Bayer AG involves the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022.
Compugen Ltd. (CGEN), a therapeutic discovery and development company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for COM701, the Company's lead immuno-oncology therapeutic antibody candidate. The patent was issued under the USPTO's pilot program providing early review for patent applications pertaining to cancer immunotherapy in support of the White House Cancer Moonshot program, and is one of less than a dozen patents granted under the program to date.
HOLON, Israel , July 24, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today that the Company will release its second quarter financial results on Wednesday, ...
Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today disclosed new data for its COM701 immuno-oncology therapeutic antibody candidate demonstrating potential for dual- and triple-combination therapy with antibodies targeting TIGIT and PD-1. In addition to monotherapy applications, this combination approach may expand the responsive cancer patient population, including those who are partially responsive or refractory to PD-1 inhibitors. Furthermore, recent expression data in human tumors point to the potential of COM701 to treat cancer patients for whom current PD-1 pathway inhibitors have shown limited efficacy.
Compugen Ltd. (CGEN), a therapeutic discovery company, announced today that it anticipates a delay of several months in the submission of an investigational new drug application (IND) for COM701, Compugen's clinical candidate antibody targeting CGEN-15029/PVRIG. Previously the Company had disclosed an expectation of IND filing in Q4 of this year. The Company was recently informed by its manufacturing service provider for COM701 - a global contract development and manufacturing organization (CDMO) - that the batch of material they manufactured for Compugen's planned GLP (good laboratory practice) toxicity studies was contaminated during the manufacturing process.
Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Michal Preminger, PhD, MBA, Executive Director at Harvard University Office of Technology Development's Harvard Medical School site, has been appointed a Director of Compugen by the Company's Board of Directors. Dr. Preminger brings to Compugen broad managerial and business experience focused on the pharma and biotech industries.